Description
The ION-Ghent guidelines for the management of immune related adverse events (irAE’s)
- You cannot add another "Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma" to your cart. View cart
Article: The ION-Ghent guidelines for the management of immune related adverse events (irAE’s)
€2.42
Reviews
There are no reviews yet.